Results: Nine patients (8.8%) showed a partial response (PR), 28 (27.5%) achieved stable
disease (SD), and 65 (63.7%) had progressive disease (PD). The disease control rate was …

Background Gefitinib and erlotinib are useful, molecular targeted agents in patients with non-
small-cell lung cancer (NSCLC) who failed previous chemotherapy. We compared the …

7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …

Background Adenosquamous carcinoma (ASC) of the lung is a rare subtype of nonsmall-cell
lung cancer (NSCLC). To date, the efficacious targeted therapy for advanced ASC remains …

INTRODUCTION: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

Results: In total, 521 patients were administered EGFR-TKI. Of these, 298 patients received
EGFR-TKI with progression-free survival less than 6 months (group A), and the other 223 …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
became an attractive therapeutic option for advanced non-small-cell lung cancer (NSCLC) …

Background The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) in squamous cell carcinoma (SCC) of the lung remains controversial, and …

Background: Erlotinib and gefitinib are epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs). They have the same mechanism of action and very similar side …